Search Results
Jun 24, 2026, 03:49 ET Lundbeck presents new Vyepti® (eptinezumab) and bocunebart migraine portfolio data at EAN 2026
migraine[5] and PROMISE-2 in chronic migraine).[6] In both trials, eptinezumab met its primary endpoint of reducing mean monthly migraine days (MMD) over weeks 1-12 in both episodic and chronic migraine. The safety of eptinezumab was evaluated in more than 2,000 adult patients with migraine who received
More news about: H. Lundbeck A/S
Jun 18, 2026, 18:46 ET Tevra Brands Launches "In Their Everywhere" Campaign as Pet Owners Prepare for Peak Tick Season
https://youtu.be/Xgtw08t3Ejc?si=rj79YcPf0mMD9GS3About Tevra BrandsTevra Brands is committed to providing high-quality, innovative pet health solutions at
More news about: Tevra Brands
May 19, 2026, 08:30 ET eschbach Unveils Seqonis, the Next Evolution of its Intelligent Operations Platform
Boston Marriott Copley Place. Attendees can visit Booth No. 3 for demonstrations of the Seqonis IOP.Wincy Fung, AVP of Digital Services, Digital MMD at Merck, will join eschbach CEO Andreas Eschbach at PMWS 2026 for a session titled "Running Pharma on Intelligence: How Merck's Intelligent Visual Factory
More news about: eschbach
Apr 19, 2026, 13:19 ET Lundbeck presents new data at AAN 2026 highlighting real-world changes in migraine-related cognitive symptoms after starting VYEPTI® (eptinezumab)
trials; episodic migraine in PROMISE-1 and chronic migraine in PROMISE-2. Eptinezumab met its primary endpoint of decrease in mean monthly migraine days (MMD) over months 1-3 in both episodic and chronic migraine. The safety of eptinezumab was evaluated in 2,076 patients with migraine who received at least
More news about: H. Lundbeck A/S
Apr 13, 2026, 03:43 ET Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting
migraine[vi] and PROMISE-2 in chronic migraine)[vii], where eptinezumab met its primary endpoint of decrease in mean monthly migraine days (MMD) over weeks 1-12 in both episodic and chronic migraine. Furthermore, the clinical trial program demonstrated a treatment benefit over placebo that was
More news about: H. Lundbeck A/S
Apr 13, 2026, 03:40 ET Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting
migraine[vi] and PROMISE-2 in chronic migraine)[vii], where eptinezumab met its primary endpoint of decrease in mean monthly migraine days (MMD) over weeks 1-12 in both episodic and chronic migraine. Furthermore, the clinical trial program demonstrated a treatment benefit over placebo that was
More news about: H. Lundbeck A/S
Mar 11, 2026, 02:40 ET 필립스 에브니아-한국외국어대학교 C&T, e스포츠 교육 지원 위한 '에브니아 e스포츠 실습실' 설립
업무 협약식은 한국외국어대학교 부총장 박중찬 교수가 사회를 맡았으며, 글로벌스포츠산업학부 e스포츠 연구센터장 류윤지 교수가 대학 측 대표로 기부 협약식에 공식 서명했다. 필립스 에브니아를 대표해 MMD 아시아태평양 및 대중국 지역 총괄 사장 Yan Lidong 대표가 협약서에 서명하며 "이번 기부 협약은 글로벌 e스포츠 교육 발전을 지원하기 위한 필립스 에브니아의 중요한 발걸음"이라며 "당사의 첨단 디스플레이 기술과 고성능 e스포츠 모니터를 통해 학생들에게 최적의
More news about: Philips Evnia
Jan 20, 2026, 09:00 ET Major Medical Devices Appoints Healthcare Industry Veteran Eric Curtis as Its Chief Executive Officer
am pleased to join MMD as the Company's Chief Executive Officer. I believe medical device innovation in AAA treatment is needed and MMD's next-generation device could become the next standard of care in a condition that impacts 35 million patients worldwide," said Mr. Curtis. "MMD has a team of experts
More news about: Major Medical Devices, Inc.
Jan 09, 2026, 09:00 ET Major Medical Devices Secures Strategic Funding to Advance Novel AAA Repair Device to Market
http://www.majormedicaldevices.com) (MMD), an emerging innovator in vascular intervention technologies with a highly differentiated, potentially quick to market device in a $3 billion market, announces strategic funding partnership with TCA Venture Group (TCA), a leading investment group based in southern California. MMD The partnership
More news about: Major Medical Devices, Inc.
Nov 12, 2025, 15:15 ET OAGi and NIIMBL Announce Release of Biopharmaceutical Manufacturing Ontologies to Advance Interoperability and Analytics
improve usability for ontology specialists and implementation teams," stated Elyse Easson, Director, Commercialization and Digital CMC Value Team, Digital MMD. The biopharmaceutical manufacturing sector has expressed strong support for the availability of this ontology and the advantages
More news about: National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)
Oct 16, 2025, 06:05 ET SuperX、NVIDIA GB300搭載のラックマウント型AIプラットフォームを発表、データセンターインフラの次世代標準を提示
48U NVIDIA MGXラック、 2296mm(H) x 600mm(W) x 1200mm(D)
More news about: SuperX AI Technology Ltd
Oct 16, 2025, 06:05 ET SuperX Launches Rack-Scale AI Platform Powered by NVIDIA GB300 Chips, Redefining Data Center Infrastructure
2296mm(H) x 600mm(W) x 1200mm(D)
More news about: SuperX AI Technology Ltd
Oct 03, 2025, 06:35 ET SuperX、最新のXN9160-B300 AIサーバーを発表 -- Blackwell UltraはBlackwellより計算能力が50%向上
8U 447mm(H) x 351mm(W) x 923mm(D)
More news about: SuperX AI Technology Ltd
Oct 03, 2025, 06:35 ET SuperX Launches the Latest XN9160-B300 AI Server, Blackwell Ultra Delivers 50% More Compute Over Blackwell
8U 447mm(H) x 351mm(W) x 923mm(D)
More news about: SuperX AI Technology Ltd
Sep 16, 2025, 07:00 ET ShiraTronics Announces Positive 12-Month Follow-Up Results from RELIEV-CM Pilot Study, Demonstrating Sustained Clinical Benefit with Investigational Implantable Neuromodulation Therapy for Chronic Migraine
Include: 9.6 average reduction in monthly headache days (MHD) from baseline9.6 average reduction in monthly migraine days (MMD) from baselineSustained improvements in migraine-specific quality of life (MSQ) across multiple domainsReduction in rescue medication
More news about: ShiraTronics, Inc.
Sep 11, 2025, 02:27 ET Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine
across the open-label period.2 The proportion of participants with a ≥50% or ≥75% MMD reduction from baseline was sustained throughout the trial, with 35.7% of patients achieving a 50% reduction in MMD by week 49-60. A trend towards increasing ≥75% response rate was also observed across the 60-weeks
More news about: H. Lundbeck A/S
Sep 11, 2025, 02:23 ET Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine
across the open-label period.2 The proportion of participants with a ≥50% or ≥75% MMD reduction from baseline was sustained throughout the trial, with 35.7% of patients achieving a 50% reduction in MMD by week 49-60. A trend towards increasing ≥75% response rate was also observed across the 60-weeks
More news about: H. Lundbeck A/S